Human Insulin Market Growth Driven by Rising Diabetes Prevalence and Technological Innovations

he global human insulin market size was USD 18.17 Billion in 2022 and is expected to register a rapid revenue CAGR of 1.9% during the forecast period. The global human insulin market is experiencing significant growth, primarily driven by the increasing prevalence of diabetes and advancements in technology. According to the World Health Organization (WHO), approximately 537 million adults worldwide were affected by diabetes in 2021, with projections indicating that this number will rise as the global population continues to grow. Notably, the elderly population, estimated at 727 million in 2020, is expected to reach around 1.5 billion by 2050, further intensifying the demand for insulin products.

A key driver of market growth is the technological advancements in diabetes care. Innovations such as recombinant DNA technology and the integration of Artificial Intelligence (AI) in production processes have enhanced productivity and energy efficiency. Additionally, the introduction of Continuous Glucose Monitoring (CGM) devices and insulin pumps has transformed insulin therapy. CGM devices allow for real-time monitoring of glucose levels, helping patients and healthcare professionals manage diabetes more effectively. Insulin pumps, which deliver insulin in a precise and controlled manner, offer significant benefits in glycemic control.

Despite these positive trends, the market faces challenges. High manufacturing costs, a shortage of skilled professionals, and strict government regulations may hinder revenue growth. The production of human insulin requires expensive equipment, making it difficult for some manufacturers to afford the necessary investments.

To Receive A PDF Sample Of The Report, Visit @https://www.emergenresearch.com/request-sample/2843

Continuous Glucose Monitoring (CGM) devices and insulin pumps represent additional technical breakthroughs revolutionizing insulin therapy. CGM devices enable real-time glucose monitoring, offering valuable insights for effective diabetes management. Similarly, insulin pumps provide precise insulin delivery, enhancing glycemic control and patient convenience.

Market Restraints

The certain factors pose challenges to market growth. Limitations in skilled workforce, high manufacturing expenses, and stringent government regulations may hinder revenue expansion. The considerable costs associated with insulin production equipment and the scarcity of proficient professionals in the field present affordability and operational constraints for manufacturers.

The global human insulin market is segmented based on product, application, and end-use. The dominance of the long-acting insulin segment is attributed to its sustained efficacy and patent protection, accounting for the largest market share in 2022. Biosimilar insulins are anticipated to register moderate growth, driven by their potential to improve patient compliance and reduce drug costs.

In terms of application, the type 1 diabetes segment is expected to hold a significant market share due to the high insulin dependency of type 1 patients, characterized as a more severe condition compared to type 2 diabetes. Conversely, the type 2 diabetes segment is projected to exhibit steady growth, fueled by the rising prevalence of the disease.

Additionally, ongoing Research & Development (R&D) efforts focus on oral insulin delivery systems, offering an alternative to insulin injections. Currently, only two systems have received FDA approval, with ORMD-0801 undergoing phase 3 clinical trials. The approval of such products presents patients with additional treatment options and enhances accessibility to insulin therapy.

To Get A Discount On The Latest Report, Visit @https://www.emergenresearch.com/request-discount/2843

In terms of end-use, the retail pharmacy segment is anticipated to dominate the market, driven by the increased accessibility of treatment options and medications. Patients find it easier to access prescribed medications and related products at local pharmacies, driving demand for these services.

Overall, the global human insulin market is on a trajectory of significant growth, propelled by the escalating prevalence of diabetes, technological advancements, and expanding treatment options. Despite challenges, the market is poised to witness substantial expansion in the coming years.

Human Insulin Top Companies and Competitive Landscape

The global human insulin market is fairly fragmented with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective human insulin solutions.

Tonghua Dongbao Pharmaceutical Co., Ltd.

Eli Lilly and Company

Biocon Ltd.

Merck & Co., Inc.

Ypsomed AG

Johnson & Johnson Private Limited

Albireo Pharma, Inc.

Amgen Inc.

Teva Pharmaceutical Industries Ltd.

WOCKHARDT

Human Insulin Latest Industry News

In November 2022, Biocon Sdn. Bhd., a subsidiary of Biocon based in Malaysia, disclosed the acquisition of a three-year contract for its recombinant human insulin brand, Insugen, awarded by the Ministry of Health (MoH) in Malaysia.

Browse Detailed Research Report @https://www.emergenresearch.com/industry-report/human-insulin-market

Human Insulin Market Segment Analysis

For the purpose of this report, Emergen Research has segmented the global human insulin market on the basis of product, application, type, end-use, and region:

Product Outlook (Revenue, USD Billion; 2019-2032)

Rapid acting insulin

Long acting insulin

Combination insulin

Biosimilar insulin

Others

Application Outlook (Revenue, USD Billion; 2019-2032)

Type 1

Type 2

Type Outlook (Revenue, USD Billion; 2019-2032)

Analog insulin

Human insulin

End-Use Outlook (Revenue, USD Billion; 2019-2032)

Hospital & clinics

Retail pharmacy

Others

Regional Outlook (Revenue, USD Billion; 2019-2032)

North America

U.S.

Canada

Europe

Germany

France

UK

Italy

Spain

Benelux

Russia

Rest of Europe

Asia Pacific

China

Japan

South Korea

India

ASEAN Countries

Oceania

Rest of APAC

Latin America

Brazil

Mexico

Rest of LATAM

Middle East & Africa

GCC Countries

Israel

Turkey

South Africa

Rest of Middle East & Africa

Buy Now: @https://www.emergenresearch.com/select-license/2843

Exploring Market Insights: A Guide to Related Reports

Human Insulin Market Size @ https://www.emergenresearch.com/industry-report/human-insulin-market/market-size

Human Insulin Market Share @ https://www.emergenresearch.com/industry-report/human-insulin-market/market-share

Human Insulin Market Trends @ https://www.emergenresearch.com/industry-report/human-insulin-market/market-trends

Human Insulin Regional Market Demand @ https://www.emergenresearch.com/industry-report/human-insulin-market/regional-market-demand

Human Insulin Market Analysis @ https://www.emergenresearch.com/industry-report/human-insulin-market/market-analysis

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.